'Ongoing challenges' force Pfizer to scrap oral RSV med from ReViral buyout

In another blow to its $525 million buyout of ReViral, Pfizer has ended development of sisunatovir, an oral inhibitor designed to treat respiratory syncytial virus (RSV) in both kids and adults.